Ajanta Pharma Limited

Mumbai – (August 4, 2015) – Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, has received final approval for its 3 ANDAs (Abbreviated New Drug Application) by US FDA (United States Food and Drug Administration)

Highlights of Q4 FY ‘15 standalone financial performance are: • Revenue from operations grew 19% at Rs. 369 cr. against Rs. 311 cr. • EBITDA growth of 25% at Rs. 141 cr. against Rs. 112 cr., EBITDA at 38% of revenue.

Mumbai, 28th January 2015: Ajanta Pharma Limited, announced sub-division of nominal value of equity shares of the Company from Rs. 5/- each to nominal value of Rs. 2/- each.

• Revenue from operations grew 21% at Rs. 363 cr. against Rs. 301 cr. • EBITDA growth of 32% at Rs. 131 cr. against Rs. 99 cr. EBITDA at 36% of revenue • Profit before Tax at Rs. 124 cr. against Rs. 90 cr., a growth of 38%

Highlights of Q2 FY ‘15 vis-a-vis Q2 FY ‘14 standalone financial performance are: • Revenue from operations grew 21% at Rs. 337 cr. against Rs. 280 cr.

Mumbai – (05th August, 2014) – Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company reported today its performance for the first quarter ended 30th June 2014.

Standalone Q4 Revenue Growth 25%, Net Profit Growth 159% Standalone FY14 Revenue Growth 32%, Net Profit Growth 118% Proposes dividend of Rs.10 per equity share of Rs.5 each, post bonus

Mumbai – (January 27, 2014) – Ajanta Pharma Limited, , a specialty focused pharmaceutical formulation company, reported its financial results today for 3rd quarter and 9 months ended December 31st 2013 with outstanding performance.

Ajanta Pharma Limited, a specialty focused pharmaceutical formulation company, reported financials today for 2nd quarter and half year ended September 30th 2013 with an outstanding performance

In yet another landmark victory to the Indian Patent Scenario, Ajanta Pharma Limited,emerged successful in revoking two composition patents of Allergan Inc.